Skip to footer
Hoofdkantoor Nederlandse Voedsel- & Waren autoriteit (NVWA - Utrecht).jpg
Photo: Martix (Michel van der Laan), CC BY-SA 4.0, via Wikimedia Commons

business

FDA warns GLP-1 drugs like Ozempic may cause permanent vision loss

FDA mandates warning labels on GLP-1 drugs like Ozempic for potential permanent vision loss risks.

Updated 1 min read

Published by Agyata NewsroomEditorial policyCorrections

Key points

  • FDA orders warning label updates for GLP-1 drugs Ozempic, Wegovy, and Mounjaro.
  • Older adults and those with diabetes or high blood pressure face higher vision loss risks.
  • Affected patients may suffer sudden, painless vision loss typically in one eye.

Why it matters. This regulatory change directly impacts patient safety protocols for millions using these widely prescribed medications, particularly older adults and those with existing metabolic conditions.

Updated Sources: Morningstar, Indiatimes, Wikipedia: Semaglutide

The US Food and Drug Administration requires manufacturers of GLP-1 weight loss drugs, including Ozempic, Wegovy, and Mounjaro, to update warning labels regarding potential permanent vision loss. This risk is elevated for older adults and individuals with diabetes or high blood pressure, who may experience sudden, painless sight loss often in just one eye. The agency cites NAION as the condition typically responsible for these visual impairments.

Latest updates

FDA warns GLP-1 drugs like Ozempic may cause permanent vision loss

The US Food and Drug Administration (FDA) has issued a safety communication requiring manufacturers of GLP-1 receptor agonists, including Ozempic, Wegovy, and Zepbound, to add warnings about potential vision loss. The agency states that the risk appears higher in older adults and individuals with pre-existing conditions such as diabetes or high blood pressure. While the exact mechanism remains under investigation, the FDA advises patients to seek immediate medical attention if they experience sudden changes in vision. This regulatory action marks a significant shift in the safety monitoring of widely prescribed weight-loss medications.

MorningstarIndiatimesWikipedia: Semaglutide

Sources

AI-assisted summary of the reporting above. Quotes are kept to one sentence. Copyright concern? See our DMCA takedown page.